Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc. (NASDAQ: GUTS) is a metabolic health company dedicated to developing minimally invasive, endoscopy-based interventions for chronic metabolic diseases, including type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Founded in 2014 and headquartered in Lexington, Massachusetts, the company seeks to address underlying intestinal pathologies that contribute to metabolic dysfunction by harnessing the therapeutic potential of targeted duodenal mucosal resurfacing.

At the core of Fractyl’s technological platform is Revita® DMR (Duodenal Mucosal Resurfacing), a catheter-based procedure performed through standard endoscopy. By gently ablating and regenerating the duodenal lining, Revita DMR aims to reset metabolic signaling pathways, improve glycemic control, and reduce hepatic fat accumulation. The company’s R&D pipeline also includes combination approaches pairing mucosal resurfacing with adjunctive pharmacotherapies and microbiome-modulating agents to extend clinical benefit across a broader patient population.

Fractyl’s Revita DMR received CE Mark approval in Europe and is being evaluated under multiple clinical trials in the United States and select international markets. The company collaborates with leading academic institutions, gastroenterology centers, and endocrinology networks to advance its clinical development program. These strategic partnerships are designed to optimize procedural protocols, patient selection criteria and long-term outcome tracking across diverse demographic and geographic cohorts.

Leadership at Fractyl Health includes CEO Dr. Aviv Bahat, who brings over two decades of experience in medical device innovation, and Chief Medical Officer Dr. Steven Stern, a gastroenterologist renowned for his expertise in endoscopic therapies. The company’s board features industry veterans from both the biopharmaceutical and medical device sectors. Together, this team is committed to transforming the treatment landscape for metabolic disease by offering durable, organ-targeted interventions that complement existing therapeutic options.

Key Stats

• Today's Range: $1.79 to $1.92
• 50-Day Range: $1.49 to $2.88
• 52-Week Range: $0.87 to $4.37
• Volume: 325,995 shs
• Average Volume: 372,579 shs
• Market Capitalization: $87.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 44% of companies evaluated by MarketBeat, and ranked 609th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Fractyl Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fractyl Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fractyl Health are expected to decrease in the coming year, from ($1.61) to ($1.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fractyl Health is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fractyl Health is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fractyl Health has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.77% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 18.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.77% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 18.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Fractyl Health has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Fractyl Health this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for GUTS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have not sold or bought any company stock.

GUTS Stock Analysis - Frequently Asked Questions

How have GUTS shares performed this year?

Fractyl Health's stock was trading at $2.06 on January 1st, 2025. Since then, GUTS stock has decreased by 13.1% and is now trading at $1.79.

How were Fractyl Health's earnings last quarter?

Fractyl Health, Inc. (NASDAQ:GUTS) posted its earnings results on Tuesday, May, 13th. The company reported ($0.49) EPS for the quarter, hitting analysts' consensus estimates of ($0.49). Fractyl Health had a negative net margin of 73,864.52% and a negative trailing twelve-month return on equity of 228.66%.
Read the conference call transcript.

When did Fractyl Health IPO?

Fractyl Health (GUTS) raised $110 million in an initial public offering on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $15.00 per share.

How do I buy shares of Fractyl Health?

Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fractyl Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 102
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Fractyl Health: $11.00
• High Price Target: $12.00
• Low Price Target: $10.00
• Potential Upside/Downside: +514.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.69 million
• Net Margins: -73,864.52%
• Pretax Margin: -148,511.67%
• Return on Equity: -228.66%
• Return on Assets: -76.74%

Debt

• Debt-to-Equity Ratio: 4.61
• Current Ratio: 2.50
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $90 thousand
• Price / Sales: 974.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 48,980,000
• Free Float: N/A
• Market Cap: $87.67 million
• Optionable: N/A
• Beta: 1.58